NASDAQ: FLNAFilana Therapeutics Inc Stock
$1.20+0.01 (+0.84%)
Updated May 19, 2026
FLNA Price
$1.20
Fair Value Price
$1.98
Market Cap
$57.97M
52 Week Low
$1.16
52 Week High
$4.98
P/E
-0.75x
P/B
0.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$77.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.59
Operating Cash Flow
-$30M
Beta
1.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FLNA Overview
Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FLNA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FLNA
Ranked#215 of 462
Ranked#215 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.45 | A | |
| $48.67 | A | |
| $1.90 | A |
Be the first to know about important FLNA news, forecast changes, insider trades & much more!
FLNA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FLNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FLNA ($1.20) is undervalued by 39.31% relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FLNA ($1.20) is significantly undervalued by 39.31% relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FLNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FLNA due diligence checks available for Premium users.
Valuation
FLNA fair value
Fair Value of FLNA stock based on Discounted Cash Flow (DCF)
Price
$1.20
Fair Value
$1.98
Undervalued by
39.31%
FLNA ($1.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FLNA ($1.20) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FLNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FLNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.75x
Industry
20.21x
Market
22.77x
FLNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.85x
Industry
4.72x
FLNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FLNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.3M
Profit Margin
0%
FLNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$108.4M
Liabilities
$40.2M
Debt to equity
0.59
FLNA's short-term assets ($87.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FLNA's short-term assets ($87.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FLNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FLNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.9M
Investing
$0.0
Financing
-$51.0k
FLNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FLNA vs Biotech Stocks
Filana Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.